Test from Staging

Jan 11, 2012

Shutterstock 2437656775

SPECT, PET refine contemporary cardiac amyloidosis assessment

August 24, 2026

Antoine Leimgruber

Swiss nuclear medicine seeks rules fit for radiopharmaceutical innovation

August 27, 2026

uMI Panvivo Family - Empowering Tomorrow for All

uMI Panvivo Family - Empowering Tomorrow for All

February 10, 2026

Shown is a 69-year-old man with a cholangiocarcinoma in the distal common bile duct. F-18 FDG-PET/CT was negative where Ga-68 FAPI-46 PET/CT showed high focal FAPI uptake in the liver hilum and surrounding lymph nodes. a-d: F-18 FDG-PET/CT, e-h: Ga-68 FAPI-46 PET/CT. a, b, e, f: Maximum intensity projections, c, g: axial fusion images, d, h: non-contrast enhanced CT.

FAPI-PET/CT shows promise in hepatopancreatobiliary cancers

August 13, 2026

SPECT, PET refine contemporary cardiac amyloidosis assessment

By Claudia Tschabuschnig

Experts highlighted SPECT/SPECT-CT as central to reliable cardiac amyloidosis imaging, while emerging PET tracers may improve early detection, disease characterization, and follow-up.

August 24, 2026

Shutterstock 2437656775

Swiss nuclear medicine seeks rules fit for radiopharmaceutical innovation

By Claudia Tschabuschnig

Funding, advanced technology, and the country’s small scale help make Switzerland an innovative environment for nuclear medicine.

August 27, 2026

Antoine Leimgruber

Leimgruber: Nuclear medicine needs regulation fit for innovation

By Claudia Tschabuschnig

In a video interview, Dr. Antoine Leimgruber, director ofdevelopment for nuclear medicine at Swiss Medical Network in Genolier, Switzerland, explores what is already changing in nuclear medicine and what continues to hold the specialty back.

August 26, 2026

FAPI-PET/CT shows promise in hepatopancreatobiliary cancers

FAPI-PET/CT could potentially improve noninvasive cancer staging, and, ultimately, clinical decision making.

August 13, 2026

Shown is a 69-year-old man with a cholangiocarcinoma in the distal common bile duct. F-18 FDG-PET/CT was negative where Ga-68 FAPI-46 PET/CT showed high focal FAPI uptake in the liver hilum and surrounding lymph nodes. a-d: F-18 FDG-PET/CT, e-h: Ga-68 FAPI-46 PET/CT. a, b, e, f: Maximum intensity projections, c, g: axial fusion images, d, h: non-contrast enhanced CT.

ITM receives Complete Response Letter for ITM-11

By AuntMinnie.com staff writers

The FDA stated that it's unable to approve the NDA in its present form.

August 10, 2026

Nuclear Medicine

Amyloid PET scores vary with reference-region choice, Spanish study finds

By Claudia Tschabuschnig

A Spanish study found that the brain region used as a reference can substantially alter Centiloid scores, while whole-cerebellum normalization produced the most consistent results.

August 5, 2026

Representative amyloid PET images acquired with flutemetamol, florbetaben, and florbetapir across a range of Centiloid values.

FDG-PET/CT sharpens surveillance after colorectal liver metastasis treatment

By Claudia Tschabuschnig

A Dutch study found that adding metabolic imaging to contrast-enhanced CT improved early detection of local tumor progression after liver ablation or resection, including disease missed by CT alone.

July 30, 2026

Three months after thermal ablation, contrast-enhanced CT (A, B) shows post-treatment changes without clear local progression, while FDG-PET/CECT (C–F) reveals focal uptake suspicious for recurrence.

Scottish team designs 10-year sustainability model for preclinical imaging

By Claudia Tschabuschnig

A Scottish team has designed a theoretical 10-year strategy for keeping a multimodal preclinical imaging facility financially viable, operationally resilient, environmentally responsible, and accessible to researchers.

July 29, 2026

Pexels Thirdman 8940356 (1)

ESMI review maps cancer biology ahead of TOPIM 2026

By Claudia Tschabuschnig

Ahead of TOPIM 2026, a new Nature Reviews Cancer article explores how molecular imaging can reveal the biological processes driving tumor growth, resistance, and immune evasion.

July 28, 2026

Overview of the hallmarks of cancer and the imaging modalitites that are being used to assess them.

ITM launches new oncology therapeutics division

By AuntMinnie.com staff writers

Lumara Bio will focus resources toward commercial readiness for ITM's lead drug candidate, lutetium-177 (Lu-177) edotreotide (ITM-11).

July 27, 2026

SPECT/CT viable over PET/CT for high-risk prostate cancer staging

Considering its broader accessibility, Tc-99m MIP-1404 CZT SPECT/CT may represent a practical alternative for primary staging.

July 24, 2026

Maximum intensity projection of Ga-68 PSMA-11 PET/CE-CT (A), Tc-99m MIP-1404 CZT SPECT/CT (B) and Tc-99m HDP CZT SPECT/CT (C) imaging. Ga-68 PSMA-11 PET/CE-CT and Tc-99m MIP-1404 CZT SPECT/CT showing tracer uptake in lymph nodes below the iliac bifurcation and above, paraaortic and left supraclavicular, bone uptake in the right proximal femur and right scapula (arrows). Tc-99m HDP CZT SPECT/CT did not show any uptake suspicious for metastatic disease. No sclerotic lesions suspicious of metastases were detected by the CT component in any of the studies. Fusion axial imaging of Ga-68 PSMA-11 PET/CE-CT (D) and Tc-99m MIP-1404 CZT SPECT/CT (E) showing uptake in lymph nodes in the left pelvic area below the iliac bifurcation (arrows). Fusion axial imaging of Ga-68 PSMA-11 PET/CE-CT (F) and Tc-99m MIP-1404 CZT SPECT/CT (G) showing uptake in the right proximal femur, not detected by Tc-99m HDP CZT SPECT/CT (H), (arrows).

CT dose, not FDG, drives chromosome damage during PET/CT

By Claudia Tschabuschnig

The findings suggest that standard-dose CT should be reserved for clearly justified diagnostic indications.

July 22, 2026

New research suggests the CT component of PET/CT, rather than the FDG tracer, is associated with measurable chromosome damage.

Page 1 of 129